Leitat projects €48M in 2023 revenue, with 20% from R&D. Its health division, founded in 2009, specializes in therapies and health predictors, focusing on personalized medicine...
Spanish pharmaceutical stocks dropped 10% in November, led by Rovi's 17.5% plunge amid profit and turnover declines. Grifols also fell 16%, impacted by OPA cancellation and...
Gotham City raises doubts about Grifols following Brookfield's withdrawal from a takeover bid, claiming the firm lacked access to crucial data. Grifols shares dropped 14%, compounding...
Roche is acquiring Poseida Therapeutics for up to $1.5 billion, emphasizing its strategic focus on innovative allogeneic CAR-T cancer therapies. Poseida’s candidate P-BCMA-ALLO1 shows promise in...
Ysios Capital joined Adcendo's $135M Series B round, the EU's largest in biotech this year, enabling Adcendo to advance its cancer-targeting ADC pipeline. Based in Spain,...
Extremadura's biotech meeting aims to build a cohesive regional community to address global challenges through innovation. Focus areas include health, agriculture, and industry, showcasing local practices...
The biosimilars market is poised for growth driven by increased R&D investment, favorable regulations, and strategic industry partnerships. Key opportunities arise from the expiration of patents...
21 Invest has launched its first healthcare-focused fund, 21 Invest Healthcare, raising €70 million with a €150 million target. The Article 9 fund will invest €10–15...
ATB Therapeutics secured €54 million in Series A funding, one of Belgium's largest early-stage biotech raises. Backed by major global investors like EQT Life Sciences and...
Sanofi's €40M capital boost will scale Thymoglobulin production for kidney transplant rejection and internalize diabetes drug Tzield development, acquired via Provention Bio. The investment enhances reliability,...